Brief: QED And Parent Company Bridgebio Announce Preclinical Data Supporting Tolerability And Activity Of Low-Dose Infigratinib In Treating Achondroplasia17/10/2019 12:05
Last trade - 00:00Last trade - 00:00Last trade - 00:00